$Data-Driven Math Model of FLT3-ITD Acute Myeloid Leukemia Reveals Potential Therapeutic Targets$

Data-Driven Math Model of FLT3-ITD Acute Myeloid Leukemia Reveals Potential Therapeutic Targets

<i>FLT3</i>-mutant acute myeloid leukemia (AML) is an aggressive form of leukemia with poor prognosis. Treatment with <i>FLT3</i> inhibitors frequently produces a clinical response, but the disease nevertheless often recurs. Recent studies have revealed system-wide gene expre...

Full description

Bibliographic Details
Main Authors:	David J. Wooten, Melat Gebru, Hong-Gang Wang, Réka Albert
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Series:	Journal of Personalized Medicine
Subjects:	acute myeloid leukemia Boolean model drug resistance network
Online Access:	https://www.mdpi.com/2075-4426/11/3/193

Similar Items

Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction
by: Sara Latini, et al.
Published: (2024-04-01)

Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia
by: Bai‐Liang He, et al.
Published: (2020-04-01)

ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia
by: Doh Yu Hwang, et al.
Published: (2020-05-01)

Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
by: Takahiro Kumode, et al.
Published: (2020-01-01)

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia
by: Xinhua Xiao, et al.
Published: (2023-11-01)

Symptomatic Patients with Hyperleukocytic FLT3-ITD Mutated Acute Myeloid Leukemia Might Benefit from Leukapheresis
by: Kiavasch Mohammad Nejad Farid, et al.
Published: (2023-12-01)

Target Therapy for Extramedullary Relapse of <i>FLT3</i>-ITD Acute Myeloid Leukemia: Emerging Data from the Field
by: Andrea Duminuco, et al.
Published: (2022-04-01)

Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis
by: Rachel Brodie, et al.
Published: (2019-12-01)

The sensitivity of the FLT3-ITD detection method is an important consideration when diagnosing acute myeloid leukemia
by: Masahiro Sakaguchi, et al.
Published: (2020-01-01)

Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia
by: Pimjai Niparuck, et al.
Published: (2019-01-01)

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia
by: Shano Naseem, et al.
Published: (2021-01-01)

A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
by: Peihong Wang, et al.
Published: (2021-07-01)

Integrating Patient-Specific Information into Logic Models of Complex Diseases: Application to Acute Myeloid Leukemia
by: Alessandro Palma, et al.
Published: (2021-02-01)

Characteristics and Outcome of FLT3-ITD-Positive Pediatric Acute Myeloid Leukemia—Experience of Polish Pediatric Leukemia and Lymphoma Study Group from 2005 to 2022
by: Małgorzata Czogała, et al.
Published: (2023-09-01)

NPM1 and FLT3-(ITD) Gene mutations and laboratory findings in patients with acute myeloid leukemia in Northwest of Iran
by: Sanaat Z, et al.
Published: (2014-10-01)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
by: R. Iannotta, et al.
Published: (2022-01-01)

High Expression of AHSP, EPB42, GYPC and HEMGN Predicts Favorable Prognosis in FLT3-ITD-Negative Acute Myeloid Leukemia
by: Gang-Zhi Zhu, et al.
Published: (2017-08-01)

Comparison of fragment analysis and PCR electrophoresis methods for the detection of FLT3‑ITD mutations in patients with acute myeloid leukemia
by: I. E. Maslyukova, et al.
Published: (2022-11-01)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
by: Tobias R. Haage, et al.
Published: (2023-05-01)

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3‐ITD
by: Yu Qian, et al.
Published: (2023-07-01)

Potential role of autophagy induced by FLT3-ITD and acid ceramidase in acute myeloid leukemia chemo-resistance: new insights
by: Hamidreza Zalpoor, et al.
Published: (2022-10-01)

Evaluation of cytokines and soluble adhesion molecules in patients with newly diagnosed acute myeloid leukemia: the role of TNF-alpha and FLT3-ITD
by: Tomas Kupsa, et al.
Published: (2016-03-01)

Frequency of FLT3/ITD Mutation in Patients with Acute Myeloid Leukaemia presenting at Combined Military Hospital, Rawalpindi
by: Anil Babar, et al.
Published: (2023-12-01)

Sorafenib - induced thyroiditis in patient with a relapse of acute myelomonocytic leukemia with FLT3-ITD mutation
by: Ya B Balzhanova, et al.
Published: (2019-08-01)

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia
by: Melat T. Gebru, et al.
Published: (2020-11-01)

An HSP90 Inhibitor Overcomes FLT3 Inhibitor Resistance in FLT3/ITD-Positive Leukemia Cells with an N676K Mutation
by: Hiraku Ogata, et al.
Published: (2023-09-01)

Prognostication refinement in NPM1‐mutated acute myeloid leukemia stratified by FLT3‐ITD status with different induction doses of cytarabine
by: Biao Wang, et al.
Published: (2023-04-01)

Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy
by: Bocchia M, et al.
Published: (2022-04-01)

Combination of an Oxindole Derivative with (−)-β-Elemene Alters Cell Death Pathways in FLT3/ITD<sup>+</sup> Acute Myeloid Leukemia Cells
by: Jowaher Alanazi, et al.
Published: (2023-07-01)

Efficacy and Synergy of Small Molecule Inhibitors Targeting <i>FLT3</i>-ITD<sup>+</sup> Acute Myeloid Leukemia
by: Javier Bregante, et al.
Published: (2021-12-01)

Targeting FLT3 Mutations in Acute Myeloid Leukemia
by: Riad El Fakih, et al.
Published: (2018-01-01)

Clinical Implications of the <i>FLT3</i>-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation
by: Madlen Jentzsch, et al.
Published: (2023-02-01)

<i>FLT3</i>-ITD Expression as a Potential Biomarker for the Assessment of Treatment Response in Patients with Acute Myeloid Leukemia
by: Diego Carbonell, et al.
Published: (2022-08-01)

Impact of <i>FLT3</i>-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study
by: Elizabeth M. Corley, et al.
Published: (2022-06-01)

The Impact of DNMT3A/FLT3-ITD/NPM1 on Patients with Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
by: Long Su
Published: (2019-02-01)

FLT3 inhibitors in acute myeloid leukemia
by: Mei Wu, et al.
Published: (2018-12-01)

Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia
by: Hend A. A. Ezelarab, et al.
Published: (2023-07-01)

TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
by: Nico Gagelmann, et al.
Published: (2021-03-01)

Autophagy Targeting and Hematological Mobilization in FLT3-ITD Acute Myeloid Leukemia Decrease Repopulating Capacity and Relapse by Inducing Apoptosis of Committed Leukemic Cells
by: Marine Dupont, et al.
Published: (2022-01-01)

Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia
by: Amy N. Sexauer, et al.
Published: (2017-11-01)